ABOUT US
We leverage our pharmaceutical heritage and Swiss quality to provide innovative solutions in respiratory health to improve patients' lives. We collaborate with global healthcare companies, researchers, and clinics to advance the field by using novel, sound-based digital biomarkers.​
EU MDR
Certified
ISO 13485
Certified
ISO 27001
Compliant
GDPR & HIPAA
Compliant
LEADERSHIP TEAM
Mitja Alge
Co-Founder & Chief Data Scientist
Laura Kütt, Phd
Chief Commercial Officer
Dr. Alexander Duschau-Wicke
Co-Founder & CEO
Michael Häberli
Co-Founder & CFO
OUR LEGACY AND
INDUSTRY COMMITMENT
After careers in Pharma and MedTech, the co-founders were eager to drive innovation and help people rather than get slowed down by corporate structures. They joined Evoleen, an incubator partnering with health industry players, co-creating new ventures to accelerate innovation. After prototyping several digital health initiatives, they started the SIVA project in coordination with the global pharmaceutical company Bayer, which was developing a novel drug targeting refractory chronic cough. From the successful initial feasibility project findings, it became clear that the team was holding the keys to addressing many important unmet needs in the cough space. They co-founded SIVA Health and have been driving the vision of providing better lives for respiratory patients ever since.
After Bayer discontinued its refractory chronic cough drug development project, SIVA Health became fully independent and owns all generated IPs. Today, the team works with several leading global pharmaceutical companies to support their efforts to develop better treatment options for respiratory patients.
2024-07 SIVA Health AG has received certification according to the European Medical Device Regulation (EU) 2017/745 for its continuous cough monitoring system. It is the first fully automated AI-based continuous ambulatory cough monitoring system that has been approved as a medical device.
2023-11 SIVA being used as the first AI-based continuous ambulatory cough measurement system in a global drug development study, providing cough profiles over several weeks
2023-07 SIVA Health AG becoming a fully independent company, owning all the IP generated.
2023-03 Start of clinical validation study in the U.S. at the Bellingham Asthma, Allergy & Immunology Clinic. Identifier: NCT05689307
2022-10 Clinical results of the SIVA validation study published in ERJ Open Research. First publication on AI-based continuous ambulatory cough monitoring over several weeks with a large number of patients.
2022-04 Certification according to EN ISO 13485:2016
2021-04 Start of clinical validation study at the University Hospital Zurich. First study on continuous cough monitoring over several weeks with a large number of patients
2020-04 SIVA Health Founded. Initiation of AI-based continuous ambulatory cough monitoring project in close collaboration with Bayer Pharmaceuticals